Is Pfizer Stock a Buy After an FDA Panel Recommended Boosters for Ages 65 and Up?

·4-min read
Is Pfizer Stock a Buy After an FDA Panel Recommended Boosters for Ages 65 and Up?

A partial victory is better than a complete loss. Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) are experiencing this firsthand. The two partners had hoped that a U.S. Food and Drug Administration (FDA) advisory committee would recommend COVID-19 vaccine boosters for all Americans ages 16 and up.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting